https://www.pharmaradar360.com/article/inadvertent-vaccination-in-pregnancy-vip-778ef4ca08495cd2Pharma Surgeen2026-07-06T16:10:47.000ZInadvertent vaccination in pregnancy (VIP)https://www.pharmaradar360.com/article/new-survey-shows-collaboration-between-pharmaceutical-industry-and-uk-academia-i-9bd1328bcc9f738fPharma Surgeen2026-07-06T16:01:53.000ZNew survey shows collaboration between pharmaceutical industry and UK academia is growinghttps://www.pharmaradar360.com/article/disclosure-uk-2025-the-11th-year-of-disclosure-uk-data-with-industry-transparenc-9706a4da64751d8bPharma Surgeen2026-07-06T16:01:03.000ZDisclosure UK 2025: the 11th year of Disclosure UK data, with industry transparency continuing to growhttps://www.pharmaradar360.com/article/hsbc-drops-pfizer-to-hold-seagen-adc-miss-leaves-43b-bet-without-catalyst-0e9f1cb5149a8d59Pharma Surgeen2026-07-06T15:58:22.000ZHSBC Drops Pfizer to Hold: Seagen ADC Miss Leaves $43B Bet Without Catalysthttps://www.pharmaradar360.com/article/biosimilar-race-heats-up-for-48-trillion-keytruda-market-a00759221a387a14Pharma Surgeen2026-07-06T15:38:21.000ZBiosimilar Race Heats Up for $48 Trillion Keytruda Markethttps://www.pharmaradar360.com/article/novartis-acquires-u-k-cancer-biotech-myricx-bio-for-1-5-billion-2eecdc96b2721668Pharma Surgeen2026-07-06T15:38:12.000ZNovartis acquires U.K. cancer biotech Myricx Bio for $1.5 billionhttps://www.pharmaradar360.com/article/why-are-drugmakers-racing-to-acquire-adc-payload-platforms-4d516a05bf02467dPharma Surgeen2026-07-06T15:31:55.000ZWhy Are Drugmakers Racing to Acquire ADC Payload Platforms?https://www.pharmaradar360.com/article/can-vibration-therapy-prevent-bone-loss-f28b4de5e5d8a606Pharma Surgeen2026-07-06T15:16:52.000ZCan vibration therapy prevent bone loss?https://www.pharmaradar360.com/article/astrazeneca-plc-stock-azn-moved-down-by-3-79-on-jul-6-what-signal-does-it-send-02b2bb6c686f7b27Pharma Surgeen2026-07-06T15:15:10.000ZAstraZeneca PLC Stock (AZN) Moved Down by 3.79% on Jul 6: What Signal Does It Send?https://www.pharmaradar360.com/article/novartis-scoops-up-uk-biotech-myricx-in-1-5-billion-cancer-push-64d7440ff5c96e77Pharma Surgeen2026-07-06T15:13:20.000ZNovartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Pushhttps://www.pharmaradar360.com/article/milestone-alert-can-fite-completes-enrollment-in-phase-3-trial-of-oral-piclideno-1a6617f68a18c5c9Pharma Surgeen2026-07-06T15:08:34.000ZMilestone Alert: Can-Fite Completes Enrollment in Phase 3 Trial of Oral Piclidenoson for Psoriasishttps://www.pharmaradar360.com/article/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list-3f73690e7dd97803Pharma Surgeen2026-07-06T15:06:37.000ZFDA Panel to Evaluate 7 Popular Peptides for Compounding Substances Listhttps://www.pharmaradar360.com/article/incidental-cavitary-pulmonary-mycobacterium-avium-complex-disease-with-possible-db9bdc5aef660871Pharma Surgeen2026-07-06T15:06:04.000ZIncidental Cavitary Pulmonary Mycobacterium avium Complex Disease With Possible Haemophilus influenzae Coinfection and Pharmacologic Barriers to Therapy: A Case Reporthttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-ending-a-clinical-trial-8d7a41f1e7e1b46ePharma Surgeen2026-07-06T15:02:31.000ZClinical trials for medicines: ending a clinical trialhttps://www.pharmaradar360.com/article/hair-loss-biotech-veradermics-up-656-since-its-ipo-credits-the-obesity-boom-7d6933cace8ee817Pharma Surgeen2026-07-06T14:56:30.000ZHair loss biotech Veradermics, up 656% since its IPO, credits the obesity boomhttps://www.pharmaradar360.com/article/clinical-investigations-for-medical-devices-5b914eac61a14f9cPharma Surgeen2026-07-06T14:54:37.000ZClinical investigations for medical deviceshttps://www.pharmaradar360.com/article/diphtheria-cases-among-asylum-seekers-in-england-2022-to-2026-3b388baae0a9b6b0Pharma Surgeen2026-07-06T14:50:54.000ZDiphtheria: cases among asylum seekers in England, 2022 to 2026https://www.pharmaradar360.com/article/new-haven-biotech-gets-one-year-notice-that-covid-therapy-s-emergency-authorizat-b1f482e9db6fb057Pharma Surgeen2026-07-06T14:38:14.000ZNew Haven biotech gets one-year notice that COVID therapy's emergency authorization will endhttps://www.pharmaradar360.com/article/the-ndaa-strengthens-government-support-for-biotech-it-can-be-even-stronger-59fff94b3e55ea54Pharma Surgeen2026-07-06T14:33:49.000ZThe NDAA Strengthens Government Support for Biotech. It Can Be Even Stronger.https://www.pharmaradar360.com/article/revolution-medicines-stock-hits-all-time-high-at-193-12-usd-ec310682154309b9Pharma Surgeen2026-07-06T14:29:28.000ZRevolution Medicines stock hits all-time high at 193.12 USDhttps://www.pharmaradar360.com/article/beyond-boston-unlikely-cities-stake-biotech-claims-c20c0c3b39ee70afPharma Surgeen2026-07-06T14:27:49.000ZBeyond Boston: Unlikely cities stake biotech claimshttps://www.pharmaradar360.com/article/the-evolution-and-impact-of-patient-support-services-a-strategic-framework-c6fe559337f961fePharma Surgeen2026-07-06T14:27:39.000ZThe Evolution and Impact of Patient Support Services: A Strategic Frameworkhttps://www.pharmaradar360.com/article/vertex-signs-letter-of-intent-loi-with-the-pan-canadian-pharmaceutical-alliance-7388369e90cd40daPharma Surgeen2026-07-06T14:22:00.000ZVertex Signs Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosishttps://www.pharmaradar360.com/article/first-in-class-oral-piclidenoson-reaches-pivotal-phase-3-enrollment-milestone-in-746fca67fa239490Pharma Surgeen2026-07-06T14:03:03.000ZFirst-in-Class Oral Piclidenoson Reaches Pivotal Phase 3 Enrollment Milestone in Plaque Psoriasishttps://www.pharmaradar360.com/article/aspen-athletics-club-delivers-inspiring-performance-at-the-comrades-marathon-d6ebbc6193b7bef6Pharma Surgeen2026-07-06T14:01:04.000ZAspen Athletics Club delivers inspiring performance at the Comrades Marathonhttps://www.pharmaradar360.com/article/katalyze-ai-raises-10-5m-to-build-the-agentic-operating-system-for-pharmaceutica-a75405fb33223dcdPharma Surgeen2026-07-06T14:00:15.000ZKatalyze AI Raises $10.5M to Build the Agentic Operating System for Pharmaceutical Companieshttps://www.pharmaradar360.com/article/why-this-biotech-up-14-since-its-breakout-is-on-the-rise-once-again-3cb9c7faa1ef94e0Pharma Surgeen2026-07-06T14:00:00.000ZWhy This Biotech, Up 14% Since Its Breakout, Is On The Rise Once Againhttps://www.pharmaradar360.com/article/regulatory-round-up-6-july-2026-a22ea0d2cf013ab4Pharma Surgeen2026-07-06T13:59:11.000ZRegulatory round-up: 6 July 2026https://www.pharmaradar360.com/article/four-major-biotech-updates-to-catch-up-on-5a45ac9fa2c61372Pharma Surgeen2026-07-06T13:39:14.000ZFour major biotech updates to catch up onhttps://www.pharmaradar360.com/article/novartis-to-buy-uk-oncology-biotech-for-up-to-1-5b-35ee66dd13d5e31aPharma Surgeen2026-07-06T13:37:00.000ZNovartis To Buy UK Oncology Biotech For Up To $1.5Bhttps://www.pharmaradar360.com/article/amp-bgtc-announces-fda-clearance-of-investigational-new-drug-application-for-gen-97e24ead04790a0fPharma Surgeen2026-07-06T13:34:58.000ZAMP® BGTC Announces FDA Clearance of Investigational New Drug Application for Gene Therapy Targeting Multiple Sulfatase Deficiencyhttps://www.pharmaradar360.com/article/improved-early-warning-systems-needed-to-reduce-medicines-supply-risks-says-abpi-a935581b9ac904b1Pharma Surgeen2026-07-06T13:25:28.000ZImproved early warning systems needed to reduce medicines supply risks, says ABPIhttps://www.pharmaradar360.com/article/abpi-celebrates-a-month-of-major-investment-commitments-into-uk-life-sciences-1c69d1d3b7170c47Pharma Surgeen2026-07-06T13:24:40.000ZABPI celebrates a month of major investment commitments into UK life scienceshttps://www.pharmaradar360.com/article/the-uk-should-seek-to-be-a-european-leader-for-rare-disease-medicine-says-new-re-2c00695aa8f36f31Pharma Surgeen2026-07-06T13:24:23.000ZThe UK should seek to be a European leader for rare disease medicine, says new reporthttps://www.pharmaradar360.com/article/life-sciences-sector-policy-delivery-1ed23c307a91887dPharma Surgeen2026-07-06T13:24:11.000ZLife Sciences Sector Policy Deliveryhttps://www.pharmaradar360.com/article/unlocking-nhs-data-to-increase-recruitment-into-clinical-trials-will-give-the-uk-8e6c13b135f9d747Pharma Surgeen2026-07-06T13:23:56.000ZUnlocking NHS data to increase recruitment into clinical trials will give the UK a competitive edge, says ABPIhttps://www.pharmaradar360.com/article/abpi-response-to-publication-of-england-s-rare-diseases-action-plan-2026-0f3502b175976952Pharma Surgeen2026-07-06T13:23:45.000ZABPI response to publication of England's Rare Diseases Action Plan 2026https://www.pharmaradar360.com/article/new-report-underlines-the-health-and-economic-opportunity-from-boosting-industry-a999f4c8c6537543Pharma Surgeen2026-07-06T13:23:34.000ZNew report underlines the health and economic opportunity from boosting industry clinical trialshttps://www.pharmaradar360.com/article/abpi-comment-on-measles-outbreak-and-childhood-vaccination-cffce6d42f542a83Pharma Surgeen2026-07-06T13:23:22.000ZABPI comment on measles outbreak and childhood vaccinationhttps://www.pharmaradar360.com/article/uk-opportunity-to-accelerate-development-of-new-medicines-4d0b479434d83278Pharma Surgeen2026-07-06T13:23:00.000ZUK opportunity to accelerate development of new medicineshttps://www.pharmaradar360.com/article/ukhsa-updates-heat-health-alerts-across-england-ed2386aedcea3cbcPharma Surgeen2026-07-06T13:22:58.000ZUKHSA updates heat health alerts across Englandhttps://www.pharmaradar360.com/article/abpi-response-to-national-cancer-plan-04cbac4225883744Pharma Surgeen2026-07-06T13:22:49.000ZABPI response to National Cancer Planhttps://www.pharmaradar360.com/article/what-fda-s-ai-warning-letter-tells-us-about-gmp-accountability-37a3cd780e7c38acPharma Surgeen2026-07-06T13:16:55.000ZWhat FDA's AI Warning Letter Tells Us About GMP Accountabilityhttps://www.pharmaradar360.com/article/vivos-otc-market-code-rdgl-has-received-investigational-device-exemption-ide-app-c7a7ee1dd07bf73bPharma Surgeen2026-07-06T13:10:16.000ZVivos (OTC market code: RDGL) has received Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) and will initiate a human clinical feasibility study of its Radiogel® Precision Radionuclide Therapy™.https://www.pharmaradar360.com/article/opinion-san-diego-helped-invent-biotech-and-must-now-fight-to-keep-it-cc0ee24c18115c03Pharma Surgeen2026-07-06T13:08:37.000ZOpinion: San Diego helped invent biotech and must now fight to keep ithttps://www.pharmaradar360.com/article/biotech-alliance-ramps-up-drug-pricing-lobbying-e6b857e82e712c69Pharma Surgeen2026-07-06T12:54:07.000ZBiotech Alliance Ramps Up Drug Pricing Lobbyinghttps://www.pharmaradar360.com/article/early-stage-scribe-wants-to-write-ipo-story-even-as-investors-favor-derisked-por-ed871922977e8167Pharma Surgeen2026-07-06T12:51:25.000ZEarly-stage Scribe wants to write IPO story even as investors favor derisked portfolioshttps://www.pharmaradar360.com/article/novartis-to-buy-uk-biotech-myricx-bio-for-up-to-1-5b-8751b8a295c63084Pharma Surgeen2026-07-06T12:50:59.000ZNovartis to buy UK biotech Myricx Bio for up to $1.5Bhttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-stock-price-news-analysis-2b09819439ca80fePharma Surgeen2026-07-06T12:48:58.000ZVeraxa Biotech (VRXA) Stock Price, News & Analysishttps://www.pharmaradar360.com/article/neurosense-joins-als-expert-webinar-on-primec-and-phase-3-plans-640d232c0ed810e7Pharma Surgeen2026-07-06T12:45:00.000ZNeuroSense joins ALS expert webinar on PrimeC and Phase 3 planshttps://www.pharmaradar360.com/article/moleculin-biotech-ceo-discusses-preliminary-miracle-trial-results-for-annamycin-ac67339453186b66Pharma Surgeen2026-07-06T12:44:00.000ZMoleculin Biotech CEO Discusses Preliminary MIRACLE Trial Results for Annamycin in Virtual Investor Segmenthttps://www.pharmaradar360.com/article/incyte-pays-1-25b-for-vega-adding-a-phase-3-bleeding-disorder-drug-c9a50a82b86313daPharma Surgeen2026-07-06T12:41:37.000ZIncyte pays $1.25B for Vega, adding a Phase 3 bleeding-disorder drughttps://www.pharmaradar360.com/article/veraxa-biotech-targets-2028-ind-filing-for-lead-candidate-77698e5440cd3521Pharma Surgeen2026-07-06T12:36:16.000ZVERAXA Biotech targets 2028 IND filing for lead candidatehttps://www.pharmaradar360.com/article/can-fite-achieves-key-pivotal-phase-3-psoriasis-milestone-with-completion-of-pat-ea81d9eaee6d31fcPharma Surgeen2026-07-06T12:35:40.000ZCan-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027https://www.pharmaradar360.com/article/fda-clears-vivos-to-test-radiogel-in-first-u-s-cancer-patients-f61b2b5e8f568cf3Pharma Surgeen2026-07-06T12:30:00.000ZFDA clears Vivos to test RadioGel in first U.S. cancer patientshttps://www.pharmaradar360.com/article/vivos-inc-otcqb-rdgl-receives-u-s-fda-approval-for-dcb0c9d9f5098f03Pharma Surgeen2026-07-06T12:30:00.000ZVivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval forhttps://www.pharmaradar360.com/article/kingdom-advances-biotech-ties-at-us-convention-9592ed358c453bbfPharma Surgeen2026-07-06T12:16:46.000ZKingdom advances biotech ties at US conventionhttps://www.pharmaradar360.com/article/inclusion-of-disadvantaged-communities-in-public-health-research-74c06688c67d0245Pharma Surgeen2026-07-06T12:14:23.000ZInclusion of disadvantaged communities in public health researchhttps://www.pharmaradar360.com/article/immuron-nasdaq-imrn-advances-imm-529-cdi-drug-with-new-partnering-push-91ff178910bfb94aPharma Surgeen2026-07-06T12:01:45.000ZImmuron (NASDAQ: IMRN) advances IMM-529 CDI drug with new partnering pushhttps://www.pharmaradar360.com/article/startups-move-to-colorado-amid-concerns-state-losing-its-luster-for-tech-compani-f2585701a2664d76Pharma Surgeen2026-07-06T12:00:57.000ZStartups move to Colorado amid concerns state losing its luster for tech companieshttps://www.pharmaradar360.com/article/hotline-iv-fluid-warmer-system-accessories-0a98a45eff8b70b9Pharma Surgeen2026-07-06T12:00:00.000ZHotline IV Fluid Warmer System & Accessorieshttps://www.pharmaradar360.com/article/opus-genetics-aligns-with-fda-on-phase-3-trial-for-lca5-therapy-a60944de8196fc3bPharma Surgeen2026-07-06T11:57:45.000ZOpus Genetics aligns with FDA on Phase 3 trial for LCA5 therapyhttps://www.pharmaradar360.com/article/scribe-notes-down-ipo-ambition-to-fund-lipid-lowering-genetic-meds-through-clini-82a7242a1fdef07bPharma Surgeen2026-07-06T11:54:55.000ZScribe notes down IPO ambition to fund lipid-lowering genetic meds through clinical trialshttps://www.pharmaradar360.com/article/roche-pens-490m-astex-breast-cancer-license-deal-35a03c0939d092b6Pharma Surgeen2026-07-06T11:54:02.000ZRoche pens $490m Astex breast cancer license dealhttps://www.pharmaradar360.com/article/trump-easing-testosterone-restrictions-sparks-health-warnings-over-radical-plan-baa4d8b8d93dc862Pharma Surgeen2026-07-06T11:49:56.000ZTrump Easing Testosterone Restrictions Sparks Health Warnings Over Radical Plan To Pump Up Men's Declining Hormone Levelshttps://www.pharmaradar360.com/article/fda-accepts-pharvaris-nda-for-oral-hae-attack-treatment-drug-fcd79fe3f0978c18Pharma Surgeen2026-07-06T11:42:11.000ZFDA accepts Pharvaris NDA for oral HAE attack treatment drughttps://www.pharmaradar360.com/article/alzheon-to-present-new-evidence-of-neurovascular-protection-and-preserved-brain-437bcf42f4b37b81Pharma Surgeen2026-07-06T11:40:29.000ZAlzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in Londonhttps://www.pharmaradar360.com/article/caris-life-sciences-launches-cancer-blood-test-caris-detect-fa4f1a0c066c49d5Pharma Surgeen2026-07-06T11:40:24.000ZCaris Life Sciences launches cancer blood test ‘Caris Detect’https://www.pharmaradar360.com/article/sarepta-announces-fda-acceptance-of-sndas-for-amondys-45-and-vyondys-53-7be94b2b54c2f9d1Pharma Surgeen2026-07-06T11:30:58.000ZSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®https://www.pharmaradar360.com/article/germany-modifies-healthcare-reforms-to-ease-burden-on-pharma-d492ac8514075061Pharma Surgeen2026-07-06T11:26:12.000ZGermany Modifies Healthcare Reforms to Ease Burden on Pharmahttps://www.pharmaradar360.com/article/opus-genetics-aligns-with-fda-on-phase-3-trial-for-lca5-therapy-20b0af33bd10222bPharma Surgeen2026-07-06T11:20:05.000ZOpus Genetics aligns with FDA on Phase 3 trial for LCA5 therapyhttps://www.pharmaradar360.com/article/call-for-urgency-to-deliver-on-global-pledge-for-antibiotic-incentives-8410651fcfb2fb21Pharma Surgeen2026-07-06T11:17:46.000ZCall for urgency to deliver on global pledge for antibiotic incentiveshttps://www.pharmaradar360.com/article/abpi-welcome-the-appointment-of-sir-hugh-taylor-to-key-role-in-voluntary-scheme-39056310c3c2adaePharma Surgeen2026-07-06T11:17:24.000ZABPI welcome the appointment of Sir Hugh Taylor to key role in Voluntary Scheme negotiationshttps://www.pharmaradar360.com/article/abpi-response-to-mhra-clinical-trials-framework-e80894ced2632da3Pharma Surgeen2026-07-06T11:17:11.000ZABPI response to MHRA clinical trials frameworkhttps://www.pharmaradar360.com/article/novo-nordisk-is-suspended-from-abpi-membership-1915d3064720b506Pharma Surgeen2026-07-06T11:16:58.000ZNovo Nordisk is suspended from ABPI membershiphttps://www.pharmaradar360.com/article/abpi-response-to-the-budget-8187ce9f0eb61de7Pharma Surgeen2026-07-06T11:16:42.000ZABPI response to the Budgethttps://www.pharmaradar360.com/article/abpi-welcomes-new-nhs-research-guidance-c5e2fd624c5585f4Pharma Surgeen2026-07-06T11:16:02.000ZABPI welcomes new NHS research guidancehttps://www.pharmaradar360.com/article/susan-rienow-of-pfizer-confirmed-as-president-of-the-abpi-377b62fd55e5be7ePharma Surgeen2026-07-06T11:15:49.000ZSusan Rienow of Pfizer confirmed as President of the ABPIhttps://www.pharmaradar360.com/article/abpi-refreshes-its-commitment-to-improve-public-involvement-in-research-f8b745e29aa13989Pharma Surgeen2026-07-06T11:15:36.000ZABPI refreshes its commitment to improve public involvement in researchhttps://www.pharmaradar360.com/article/veraxa-biotech-targets-2028-ind-filing-for-lead-candidate-by-investing-com-d31c4febc8681324Pharma Surgeen2026-07-06T11:15:05.000ZVERAXA Biotech targets 2028 IND filing for lead candidate By Investing.comhttps://www.pharmaradar360.com/article/veraxa-biotech-ag-provides-pipeline-and-partnering-update-advances-bitac-develop-ee42babd2c9a876bPharma Surgeen2026-07-06T11:12:00.000ZVERAXA Biotech AG Provides Pipeline and Partnering Update, Advances BiTAC Development Strategyhttps://www.pharmaradar360.com/article/opus-genetics-reaches-fda-alignment-on-phase-3-design-for-opgx-lca5-bla-may-be-s-a7209b25c8151a6cPharma Surgeen2026-07-06T11:12:00.000ZOpus Genetics Reaches FDA Alignment on Phase 3 Design for OPGx-LCA5; BLA May Be Submitted Based on 6-Month Datahttps://www.pharmaradar360.com/article/invivyd-announces-receipt-of-twelve-months-advanced-notice-of-emergency-use-auth-c2a83c7978ea76d9Pharma Surgeen2026-07-06T11:08:15.000ZInvivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDAhttps://www.pharmaradar360.com/article/opus-genetics-announces-fda-alignment-on-phase-3-registrational-trial-design-for-83bff0a95308e338Pharma Surgeen2026-07-06T11:07:44.000ZOpus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Diseasehttps://www.pharmaradar360.com/article/can-fite-nyse-american-canf-reaches-key-phase-3-psoriasis-interim-analysis-miles-8e5e833a964b01a8Pharma Surgeen2026-07-06T11:03:38.000ZCan-Fite (NYSE American: CANF) reaches key Phase 3 psoriasis interim analysis milestonehttps://www.pharmaradar360.com/article/pemgarda-faces-2027-eua-end-as-invivyd-talks-next-steps-with-fda-ea8b03d54596a588Pharma Surgeen2026-07-06T11:01:00.000ZPEMGARDA faces 2027 EUA end as Invivyd talks next steps with FDAhttps://www.pharmaradar360.com/article/fda-accepts-pharvaris-nda-for-oral-hae-attack-treatment-drug-by-investing-com-ebefbc7c57bba31dPharma Surgeen2026-07-06T11:00:03.000ZFDA accepts Pharvaris NDA for oral HAE attack treatment drug By Investing.comhttps://www.pharmaradar360.com/article/belite-bio-takes-phase-3-stargardt-disease-data-to-two-eye-meetings-3a40c685b2536738Pharma Surgeen2026-07-06T11:00:00.000ZBelite Bio takes Phase 3 Stargardt disease data to two eye meetingshttps://www.pharmaradar360.com/article/can-fite-s-psoriasis-study-reaches-interim-analysis-after-247-patients-enrolled-2d2c99ffafabf338Pharma Surgeen2026-07-06T11:00:00.000ZCan-Fite’s psoriasis study reaches interim analysis after 247 patients enrolledhttps://www.pharmaradar360.com/article/opus-genetics-clears-fda-design-for-phase-3-trial-in-childhood-blindness-32e9e777f25a5955Pharma Surgeen2026-07-06T11:00:00.000ZOpus Genetics clears FDA design for Phase 3 trial in childhood blindnesshttps://www.pharmaradar360.com/article/veraxa-says-its-bitac-cancer-pipeline-is-drawing-partner-interest-5e5daa943376e675Pharma Surgeen2026-07-06T11:00:00.000ZVERAXA says its BiTAC cancer pipeline is drawing partner interesthttps://www.pharmaradar360.com/article/can-fite-achieves-key-pivotal-phase-3-psoriasis-milestone-with-completion-of-pat-7b17e29fb7858796Pharma Surgeen2026-07-06T11:00:00.000ZCan-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027https://www.pharmaradar360.com/article/ionis-completes-enrollment-in-pivotal-cohort-of-the-phase-3-reveal-study-evaluat-d27c4fb074a833a7Pharma Surgeen2026-07-06T11:00:00.000ZIonis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndromehttps://www.pharmaradar360.com/article/pharvaris-announces-fda-acceptance-of-nda-for-deucrictibant-ir-capsule-for-on-de-5d9a196c6312ea2ePharma Surgeen2026-07-06T11:00:00.000ZPharvaris Announces FDA Acceptance of NDA for Deucrictibant IR Capsule for On-Demand Treatment of HAE Attackshttps://www.pharmaradar360.com/article/pharvaris-wins-fda-review-for-oral-hae-attack-treatment-3314d800712b5914Pharma Surgeen2026-07-06T10:50:00.000ZPharvaris wins FDA review for oral HAE attack treatmenthttps://www.pharmaradar360.com/article/swiss-drugmaker-novartis-buys-uk-biotech-firm-in-1-5bn-deal-19b02ea12f163d29Pharma Surgeen2026-07-06T10:49:15.000ZSwiss drugmaker Novartis buys UK biotech firm in $1.5bn dealhttps://www.pharmaradar360.com/article/maharashtra-fda-tightens-milk-safety-rules-7039750cf431b278Pharma Surgeen2026-07-06T10:48:18.000ZMaharashtra FDA tightens milk safety ruleshttps://www.pharmaradar360.com/article/maharashtra-fda-flags-three-beauty-creams-over-toxic-mercury-and-lead-levels-e704186be85e7b80Pharma Surgeen2026-07-06T10:20:45.000ZMaharashtra FDA flags three beauty creams over toxic mercury and lead levelshttps://www.pharmaradar360.com/article/nhs-sets-first-ever-staff-standards-to-tackle-racism-and-violence-12a37bcb5ba604c4Pharma Surgeen2026-07-06T10:13:19.000ZNHS sets first-ever staff standards to tackle racism and violencehttps://www.pharmaradar360.com/article/ataibeckley-announces-last-patient-dosed-in-phase-2b-elumina-trial-of-vls-01-for-639f4cd3193a7147Pharma Surgeen2026-07-06T10:11:00.000ZAtaiBeckley Announces Last Patient Dosed in Phase 2b Elumina Trial of VLS-01 for Treatment-Resistant Depression; Topline Data Expected in Q4 2026https://www.pharmaradar360.com/article/novartis-to-acquire-myricx-bio-in-up-to-1-5bn-deal-c0896510ee5612eaPharma Surgeen2026-07-06T10:08:54.000ZNovartis to acquire Myricx Bio in up to $1.5bn dealhttps://www.pharmaradar360.com/article/immuron-advances-imm-529-clostridioides-difficile-infection-partnering-strategy-ea876d4d4ce778c8Pharma Surgeen2026-07-06T10:07:09.000ZImmuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategyhttps://www.pharmaradar360.com/article/should-dayquil-be-legal-6ed5ddb208bb649ePharma Surgeen2026-07-06T10:06:46.000ZShould DayQuil be legal?https://www.pharmaradar360.com/article/reshoring-pharma-and-biotech-manufacturing-ahead-of-this-summer-s-tariff-deadlin-6b32118f49560292Pharma Surgeen2026-07-06T10:02:27.000ZReshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Lasthttps://www.pharmaradar360.com/article/toxic-fairness-creams-linked-to-kidney-disease-in-18-women-6878c877e955907bPharma Surgeen2026-07-06T10:01:16.000ZToxic Fairness Creams Linked to Kidney Disease in 18 Womenhttps://www.pharmaradar360.com/article/immuron-seeks-partner-for-gut-infection-drug-imm-529-c7b751e144b4b4f0Pharma Surgeen2026-07-06T10:00:00.000ZImmuron seeks partner for gut infection drug IMM-529https://www.pharmaradar360.com/article/a-decade-in-deals-houston-biotech-vc-deals-gradually-increasing-after-ups-and-do-fe3f0df4454cdd87Pharma Surgeen2026-07-06T10:00:00.000ZA decade in deals: Houston biotech VC deals gradually increasing after ups and downshttps://www.pharmaradar360.com/article/alzheon-to-present-new-evidence-of-neurovascular-protection-and-preserved-brain-8c2939d28114cbcaPharma Surgeen2026-07-06T10:00:00.000ZAlzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in Londonhttps://www.pharmaradar360.com/article/5-biotech-stocks-that-delivered-100-to-300-gains-did-your-winning-trades-offset-d034e442512d022bPharma Surgeen2026-07-06T09:51:00.000Z5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses?https://www.pharmaradar360.com/article/departmental-minute-on-public-dividend-capital-write-off-2025-to-2026-e362405845de73d3Pharma Surgeen2026-07-06T09:46:09.000ZDepartmental minute on public dividend capital write-off: 2025 to 2026https://www.pharmaradar360.com/article/newsletter-20-df9bc8c342e9de8fPharma Surgeen2026-07-06T09:38:22.000ZNewsletter #20https://www.pharmaradar360.com/article/germany-modifies-healthcare-reforms-to-ease-burden-on-pharma-3b31af9ccf0c0d7cPharma Surgeen2026-07-06T09:23:49.000ZGermany Modifies Healthcare Reforms to Ease Burden on Pharmahttps://www.pharmaradar360.com/article/maharashtra-fda-mandates-free-potable-water-in-all-hotels-and-restaurants-317f18e4dabbe072Pharma Surgeen2026-07-06T09:12:43.000ZMaharashtra FDA Mandates Free Potable Water in All Hotels and Restaurantshttps://www.pharmaradar360.com/article/novartis-to-pay-1-1b-upfront-for-myricx-to-expand-adc-pipeline-30acd7817780d25aPharma Surgeen2026-07-06T09:10:00.000ZNovartis to pay $1.1B upfront for Myricx to expand ADC pipelinehttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-edesa-biotech-inc-nasdaq-edsa-0b3a9b3f40ef48ccPharma Surgeen2026-07-06T09:05:52.000ZEnterprise value to EBIT forward of Edesa Biotech, Inc. – NASDAQ:EDSAhttps://www.pharmaradar360.com/article/meningococcal-b-menb-time-limited-vaccination-offer-c40ee43363d9a479Pharma Surgeen2026-07-06T09:00:02.000ZMeningococcal B (MenB) time limited vaccination offerhttps://www.pharmaradar360.com/article/how-evogene-is-changing-the-future-for-the-pharma-and-agriculture-markets-5efe6d7c986d8dc6Pharma Surgeen2026-07-06T08:57:31.000ZHow Evogene is changing the future for the pharma and agriculture marketshttps://www.pharmaradar360.com/article/korea-pharma-biotech-stocks-head-for-event-driven-second-half-a2cc44035f1cfa5dPharma Surgeen2026-07-06T08:54:44.000ZKorea Pharma, Biotech Stocks Head for Event-Driven Second Halfhttps://www.pharmaradar360.com/article/i-spoke-to-anthropic-s-ceo-about-how-ai-may-affect-biotech-here-s-what-i-learned-9fad86120fd8512ePharma Surgeen2026-07-06T08:33:59.000ZI spoke to Anthropic’s CEO about how AI may affect biotech. Here’s what I learnedhttps://www.pharmaradar360.com/article/zhejiang-conba-pharmaceutical-s-subsidiaries-sign-licensing-agreement-with-adneu-7fb287f36e3d745bPharma Surgeen2026-07-06T08:32:59.000ZZhejiang CONBA Pharmaceutical's Subsidiaries Sign Licensing Agreement With Adneurishttps://www.pharmaradar360.com/article/greater-bay-area-emerges-as-launchpad-for-china-s-biotech-rise-a0ff1a14c3c11672Pharma Surgeen2026-07-06T08:31:10.000ZGreater Bay Area emerges as launchpad for China's biotech risehttps://www.pharmaradar360.com/article/nhs-staff-standards-bb9d2a72502e72d3Pharma Surgeen2026-07-06T08:30:06.000ZNHS staff standardshttps://www.pharmaradar360.com/article/novartis-buys-uk-adc-biotech-myricx-bio-in-up-to-1-5bn-deal-5a88d5fca3fe183cPharma Surgeen2026-07-06T08:23:23.000ZNovartis buys UK ADC biotech Myricx Bio in up to $1.5bn dealhttps://www.pharmaradar360.com/article/price-to-book-forward-of-beijing-beilu-pharmaceutical-co-ltd-class-a-szse-300016-f708a92f2d348cc1Pharma Surgeen2026-07-06T08:07:51.000ZPrice to book forward of Beijing Beilu Pharmaceutical Co., Ltd. Class A – SZSE:300016https://www.pharmaradar360.com/article/maharashtra-fda-orders-recall-of-pak-origin-goree-fairness-creams-two-others-ove-9c973f588155b31dPharma Surgeen2026-07-06T07:57:26.000ZMaharashtra FDA orders recall of Pak-origin Goree fairness creams, two others over toxic mercury, lead levelshttps://www.pharmaradar360.com/article/elevation-point-wealth-partners-llc-makes-new-1-33-million-investment-in-teva-ph-00528a127c4a505aPharma Surgeen2026-07-06T07:55:31.000ZElevation Point Wealth Partners LLC Makes New $1.33 Million Investment in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/doctor-at-ou-health-leads-new-clinical-trial-for-stage-1-lung-cancer-patients-4916613f488c7a16Pharma Surgeen2026-07-06T07:48:54.000ZDoctor at OU Health leads new clinical trial for stage 1 lung cancer patientshttps://www.pharmaradar360.com/article/novartis-to-buy-uk-biotech-myricx-bio-in-1-5bn-deal-ab3db980af7aeca2Pharma Surgeen2026-07-06T07:46:19.000ZNovartis to buy UK biotech Myricx Bio in $1.5bn dealhttps://www.pharmaradar360.com/article/celltrion-files-amendment-for-u-s-phase-3-trial-of-keytruda-biosimilar-ct-p51-7e387284880d63f6Pharma Surgeen2026-07-06T07:44:51.000ZCelltrion Files Amendment for U.S. Phase 3 Trial of Keytruda Biosimilar CT-P51https://www.pharmaradar360.com/article/48-trillion-won-keytruda-biosimilar-race-heats-up-b1553a6b11b9e1dfPharma Surgeen2026-07-06T07:41:49.000Z48 Trillion Won Keytruda Biosimilar Race Heats Uphttps://www.pharmaradar360.com/article/algenomics-ceo-sungwook-lee-invited-as-speaker-at-rna-symposium-and-global-bio-c-8d702931f32cc8bcPharma Surgeen2026-07-06T07:33:33.000ZAlgenomics CEO Sungwook Lee Invited as Speaker at RNA Symposium and Global Bio Conferencehttps://www.pharmaradar360.com/article/ai-is-transforming-drug-discovery-here-is-the-next-trillion-dollar-biotech-oppor-a5e37ce75ab9c101Pharma Surgeen2026-07-06T07:30:27.000ZAI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunityhttps://www.pharmaradar360.com/article/statement-on-pabs-instrument-at-the-seventh-meeting-of-the-intergovernmental-wor-eaaaa465dccea49aPharma Surgeen2026-07-06T07:29:13.000ZStatement on PABS Instrument at the seventh meeting of the Intergovernmental Working Group (IGWG 7) on the WHO Pandemic Agreementhttps://www.pharmaradar360.com/article/cannabis-formula-granted-breakthrough-therapy-designation-by-fda-for-pain-treatm-38ed0166ea37a68dPharma Surgeen2026-07-06T07:16:02.000ZCannabis Formula Granted "Breakthrough Therapy Designation" by FDA for Pain Treatmenthttps://www.pharmaradar360.com/article/travere-therapeutics-wins-much-awaited-approval-for-drug-in-rare-kidney-disease-1174c8bccb244c2aPharma Surgeen2026-07-06T07:06:30.000ZTravere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Diseasehttps://www.pharmaradar360.com/article/nicox-s-ncx-470-new-drug-application-submitted-in-the-united-states-by-kowa-5fe07132926e4969Pharma Surgeen2026-07-06T07:02:57.000ZNicox’s NCX 470 new drug application submitted in the United States by Kowahttps://www.pharmaradar360.com/article/otsuka-pharmaceutical-s-subsidiary-astex-enters-exclusive-research-collaboration-2a45c2feee865884Pharma Surgeen2026-07-06T07:00:00.000ZOtsuka Pharmaceutical's Subsidiary Astex Enters Exclusive Research Collaboration and License Agreement with Genentech for Breast Cancer Therapy Programhttps://www.pharmaradar360.com/article/the-geroscience-biomarker-gap-why-immune-aging-endpoints-are-about-to-reshape-tr-94b04b8b6422293bPharma Surgeen2026-07-06T06:53:53.000ZThe Geroscience Biomarker Gap: Why Immune Aging Endpoints Are About to Reshape Trial Designhttps://www.pharmaradar360.com/article/futura-medical-new-us-eroxon-deal-and-positive-wsd4000-women-s-health-data-d6ddbf54c7aa64d0Pharma Surgeen2026-07-06T06:28:34.000ZFutura Medical: new US Eroxon deal and positive WSD4000 women's health datahttps://www.pharmaradar360.com/article/abivax-stock-surges-on-obefazimod-safety-data-cancer-concerns-cd9bcda14ba29638Pharma Surgeen2026-07-06T06:27:44.000ZAbivax stock surges on obefazimod safety data, cancer concernshttps://www.pharmaradar360.com/article/pune-fda-shuts-down-mathura-pure-veg-temporarily-over-food-safety-violations-d5d40274f036558bPharma Surgeen2026-07-06T06:26:55.000ZPune: FDA Shuts Down Mathura Pure Veg Temporarily Over Food Safety Violationshttps://www.pharmaradar360.com/article/glenmark-pharma-jumps-over-2-on-launch-of-olanzapine-single-dose-vial-c04486885cb3a13bPharma Surgeen2026-07-06T06:11:16.000ZGlenmark Pharma jumps over 2% on launch of Olanzapine single-dose vialhttps://www.pharmaradar360.com/article/lotte-chairman-declares-biotech-a-new-core-business-49ca2d9f080ffa58Pharma Surgeen2026-07-06T06:03:00.000ZLotte chairman declares biotech a new core businesshttps://www.pharmaradar360.com/article/draft-for-comments-amendment-to-fda-circular-no-2025-001-entitled-guidelines-on-3da59bfe76812191Pharma Surgeen2026-07-06T06:00:41.000ZDraft for Comments || Amendment to FDA Circular No. 2025-001 entitled “Guidelines on the Classification of Vitamins and Minerals for Food/Dietary Supplements for Adults under Processed Food Product, Repealing the Level Set for Food in the Office Order Nhttps://www.pharmaradar360.com/article/mah-fda-warns-against-3-beauty-creams-after-tests-detect-excessive-mercury-lead-e450c39945bcbc34Pharma Surgeen2026-07-06T05:56:01.000ZMah FDA warns against 3 beauty creams after tests detect excessive mercury, leadhttps://www.pharmaradar360.com/article/black-diamond-therapeutics-positive-phase-2-results-offer-an-upside-nasdaq-bdtx-d3f29596e7181706Pharma Surgeen2026-07-06T05:51:02.000ZBlack Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX)https://www.pharmaradar360.com/article/what-nppa-s-renewed-focus-on-form-iii-reporting-means-for-pharmaceutical-compani-36737f32519f6bf6Pharma Surgeen2026-07-06T05:43:03.000ZWhat NPPA's Renewed Focus on Form III Reporting Means for Pharmaceutical Companieshttps://www.pharmaradar360.com/article/aussie-super-funds-hit-the-jackpot-in-2b-uk-biotech-deal-20bb6235a8782258Pharma Surgeen2026-07-06T05:38:00.000ZAussie super funds hit the jackpot in $2b UK biotech dealhttps://www.pharmaradar360.com/article/cash-per-share-of-gin-hwa-biotech-inc-tpex-7806-b120a5be5e9ae743Pharma Surgeen2026-07-06T05:29:09.000ZCash per share of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/will-these-upcoming-milestones-re-rate-the-stock-ac86981f32544d60Pharma Surgeen2026-07-06T05:19:08.000ZWill These Upcoming Milestones Re-rate The Stock?https://www.pharmaradar360.com/article/china-hk-stocks-gain-as-ai-enthusiasm-broadens-to-farming-biotech-sectors-bc64b39ec0deee35Pharma Surgeen2026-07-06T04:43:20.000ZChina, HK stocks gain as AI enthusiasm broadens to farming, biotech sectorshttps://www.pharmaradar360.com/article/positive-phase-2-results-for-new-oral-glp-1-for-obesity-591f4b2f1456e1d1Pharma Surgeen2026-07-06T04:35:17.000ZPositive Phase 2 Results for New Oral GLP-1 for Obesityhttps://www.pharmaradar360.com/article/opinion-the-fda-must-put-biotech-at-its-center-or-continue-to-cede-early-researc-ed9c9fa4d0b70a2bPharma Surgeen2026-07-06T04:25:58.000ZOpinion: The FDA must put biotech at its center or continue to cede early research to Chinahttps://www.pharmaradar360.com/article/despite-chaos-and-churn-fda-decisions-hold-mostly-steady-in-h1-2026-4b2bc0f527ba9fd1Pharma Surgeen2026-07-06T04:05:57.000ZDespite chaos and churn, FDA decisions hold mostly steady in H1 2026https://www.pharmaradar360.com/article/triple-digit-gains-haven-t-killed-this-biotech-s-upside-here-s-what-comes-next-aa1124c7403c971fPharma Surgeen2026-07-06T04:02:30.000ZTriple-Digit Gains Haven’t Killed This Biotech’s Upside. Here’s What Comes Nexthttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tse-4502-is-up-5-3-after-new-insilico-ai-drug-discovery-de-c4902bf81718f89fPharma Surgeen2026-07-06T03:37:09.000ZTakeda Pharmaceutical (TSE:4502) Is Up 5.3% After New Insilico AI Drug Discovery Deal - Has The Bull Case Changed?https://www.pharmaradar360.com/article/etfs-investing-in-takeda-pharmaceutical-co-ltd-sponsored-adr-stocks-3b861f7d475c5711Pharma Surgeen2026-07-06T03:17:50.000ZETFs Investing in Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stockshttps://www.pharmaradar360.com/article/shinsa-software-as-a-medical-device-samd-page-updated-8fd558e9473c46f8Pharma Surgeen2026-07-06T03:00:00.000Z[SHINSA]Software as a Medical Device (SaMD) page updatedhttps://www.pharmaradar360.com/article/bulgaria-moves-to-shore-up-generic-medicines-access-amid-shortage-crisis-a7869e4b2ddd5bd2Pharma Surgeen2026-07-06T00:57:34.000ZBulgaria moves to shore up generic medicines access amid shortage crisishttps://www.pharmaradar360.com/article/startup-island-taiwan-bridges-tech-hubs-launching-east-coast-biotech-initiative-f66c47affdedadcaPharma Surgeen2026-07-06T00:27:00.000ZStartup Island TAIWAN Bridges Tech Hubs, Launching East Coast Biotech Initiative in Bostonhttps://www.pharmaradar360.com/article/revolution-medicines-is-up-nearly-140-in-2026-is-the-hot-biotech-stock-still-a-b-93d330af38b11c76Pharma Surgeen2026-07-06T00:15:00.000ZRevolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?https://www.pharmaradar360.com/article/regeneron-filed-form-8-k-794be60927f29c49Pharma Surgeen2026-07-06T00:00:00.000ZRegeneron filed Form 8-Khttps://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-7996769044e442e1Pharma Surgeen2026-07-06T00:00:00.000ZNovo Nordisk filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-32c6c53e7a0ca514Pharma Surgeen2026-07-06T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-5842b2375b7eca30Pharma Surgeen2026-07-06T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-8eb0bf92d1ae2f4fPharma Surgeen2026-07-06T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-948222f1b88b0028Pharma Surgeen2026-07-06T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-d002e7cc25c4e109Pharma Surgeen2026-07-06T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-706a71e62515d0a5Pharma Surgeen2026-07-06T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-fa51638b6af55ea6Pharma Surgeen2026-07-06T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-9b3c1428472b8eddPharma Surgeen2026-07-06T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-19a412ba063fce2dPharma Surgeen2026-07-06T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-d742ebe57b8b944ePharma Surgeen2026-07-06T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-b32f42492b21eab2Pharma Surgeen2026-07-06T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-3c1043f1a117e42ePharma Surgeen2026-07-06T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-53db95eaaf94cec2Pharma Surgeen2026-07-06T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-e7df32506d97c64ePharma Surgeen2026-07-06T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-7d2cc969f2df410bPharma Surgeen2026-07-06T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/endo-operations-limited-et-al-withdrawal-of-approval-of-34-new-drug-applications-0fe04ab6d448b9fcPharma Surgeen2026-07-06T00:00:00.000ZEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applicationshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-199f19173a542002Pharma Surgeen2026-07-06T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/temporary-placement-of-7-hydroxymitragynine-above-a-specified-threshold-in-sched-92546f760ae2e0f2Pharma Surgeen2026-07-06T00:00:00.000ZTemporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I; Request for Informationhttps://www.pharmaradar360.com/article/patient-safety-organizations-voluntary-relinquishment-for-the-cassatt-patient-sa-6766b6300bea36dfPharma Surgeen2026-07-06T00:00:00.000ZPatient Safety Organizations: Voluntary Relinquishment for the Cassatt Patient Safety Organizationhttps://www.pharmaradar360.com/article/calendar-year-2027-home-health-prospective-payment-system-hh-pps-rate-update-req-3a9334c892e48d51Pharma Surgeen2026-07-06T00:00:00.000ZCalendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the Expanded HH Value-Based Purchasing Model; Medicare Provider Enrollment, Durable Medical Equipment (DME), and DME, Prosthetics, Orthotics, and Supplies (DMEPOS) Pohttps://www.pharmaradar360.com/article/expedited-investigational-new-drug-pilot-program-request-for-information-correct-2513bdc5da3cf1e1Pharma Surgeen2026-07-06T00:00:00.000ZExpedited Investigational New Drug Pilot Program; Request for Information; Correctionhttps://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-generic-clearance-for-nih-citizen-sci-f5ec33c9d6a787e9Pharma Surgeen2026-07-06T00:00:00.000ZProposed Collection; 60-day Comment Request; Generic Clearance for NIH Citizen Science and Crowdsourcing Projects (Office of the Director)https://www.pharmaradar360.com/article/schedules-of-controlled-substances-temporary-placement-of-mitragynine-pseudoindo-1aa191820c019a08Pharma Surgeen2026-07-06T00:00:00.000ZSchedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule Ihttps://www.pharmaradar360.com/article/schedules-of-controlled-substance-temporary-placement-of-7-hydroxymitragynine-ab-eabb6b75cd05a680Pharma Surgeen2026-07-06T00:00:00.000ZSchedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule Ihttps://www.pharmaradar360.com/article/privacy-act-of-1974-matching-program-360d8559fb466d0dPharma Surgeen2026-07-06T00:00:00.000ZPrivacy Act of 1974; Matching Programhttps://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-2a64b20c2642d6d5Pharma Surgeen2026-07-06T00:00:00.000ZProposed Data Collection Submitted for Public Comment and Recommendationshttps://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-4298c7d56bd0f39fPharma Surgeen2026-07-06T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-c32590e3f5bd7295Pharma Surgeen2026-07-06T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearingshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-bio-c4bbe26b4f6c5b34Pharma Surgeen2026-07-06T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirementshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-3f7ab81c9f30ed02Pharma Surgeen2026-07-06T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Deviceshttps://www.pharmaradar360.com/article/determination-that-vasopressin-in-sodium-chloride-vasopressin-0-9-injection-50-u-c7aba6861bc2d564Pharma Surgeen2026-07-06T00:00:00.000ZDetermination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectivenesshttps://www.pharmaradar360.com/article/le-quebec-est-la-premiere-province-a-inscrire-pr-okedi-md-suspension-injectable-02134888f0ad8056Pharma Surgeen2026-07-06T00:00:00.000ZLe Québec est la première province à inscrire Pr OKEDI MD (suspension injectable à libération prolongée de rispéridone) sur la liste des médicaments remboursés par le régime public pour le traitement de la schizophréniehttps://www.pharmaradar360.com/article/quebec-is-the-first-province-to-list-pr-okedi-mc-extended-release-injectable-sus-5b3d15320f0ea413Pharma Surgeen2026-07-06T00:00:00.000ZQuébec is the first province to list Pr OKEDI MC (extended-release injectable suspension of risperidone) on the public drug reimbursement formulary for the treatment of schizophreniahttps://www.pharmaradar360.com/article/oropharyngeal-dysphagia-and-gastroesophageal-reflux-disease-in-lung-transplant-p-90c777494cce8317Pharma Surgeen2026-07-06T00:00:00.000ZOropharyngeal dysphagia and gastroesophageal reflux disease in lung transplant patients: a systematic review and meta-analysis of incidence, risk factors, and clinical outcomeshttps://www.pharmaradar360.com/article/abc-will-trial-using-ai-for-journalism-what-are-the-risks-and-benefits-526d7c54b00391e3Pharma Surgeen2026-07-06T00:00:00.000ZABC will trial using AI for journalism. What are the risks and benefits?https://www.pharmaradar360.com/article/peer-review-report-for-the-institutional-black-box-of-friction-between-digital-a-61c4d9388715100dPharma Surgeen2026-07-06T00:00:00.000ZPeer Review Report For: The Institutional Black Box of Friction Between Digital Agility Demands and Clinical Bureaucracy in Hospital Social Media Management [version 2; peer review: 2 approved]https://www.pharmaradar360.com/article/choline-pet-ct-in-the-psma-era-clinical-repositioning-biological-perspectives-an-f8d89fc97513b334Pharma Surgeen2026-07-06T00:00:00.000ZCholine PET/CT in the PSMA Era: Clinical Repositioning, Biological Perspectives, and Emerging Applicationshttps://www.pharmaradar360.com/article/clinical-efficacy-of-stmipo-in-the-management-of-distal-one-third-fibular-fractu-df5e94b1987e5b96Pharma Surgeen2026-07-06T00:00:00.000ZClinical efficacy of STMIPO in the management of distal one-third fibular fractureshttps://www.pharmaradar360.com/article/association-between-urea-to-creatinine-ratio-trajectories-and-clinical-outcomes-f71949fe6777b9f7Pharma Surgeen2026-07-06T00:00:00.000ZAssociation between urea-to-creatinine ratio trajectories and clinical outcomes in chronic critical illness patients: a retrospective cohort studyhttps://www.pharmaradar360.com/article/a-novel-optimized-surgical-strategy-for-secondary-hyperparathyroidism-clean-para-10f5594b85301407Pharma Surgeen2026-07-06T00:00:00.000ZA novel optimized surgical strategy for secondary hyperparathyroidism: clean parathyroidectomy combined with autotransplantation and its clinical analysishttps://www.pharmaradar360.com/article/effectiveness-of-occupational-therapy-handwriting-interventions-for-preschoolers-0a340233f477482dPharma Surgeen2026-07-06T00:00:00.000ZEffectiveness of occupational-therapy handwriting interventions for Preschoolers (Age Group 4–6)https://www.pharmaradar360.com/article/assessment-of-knowledge-attitude-and-practices-regarding-prevention-of-catheter-ffe3f7a7a54e2421Pharma Surgeen2026-07-06T00:00:00.000ZAssessment of Knowledge, Attitude, and Practices Regarding Prevention of Catheter-Associated Urinary Tract Infections Among Nursing Staff: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/development-of-stratum-corneum-lipid-liposomes-for-topical-drug-delivery-5da47dc922289b31Pharma Surgeen2026-07-06T00:00:00.000ZDevelopment of Stratum Corneum Lipid Liposomes for Topical Drug Deliveryhttps://www.pharmaradar360.com/article/effect-of-different-doses-of-ondansetron-on-hemodynamic-status-in-patients-under-bc4caeb4bee60292Pharma Surgeen2026-07-06T00:00:00.000ZEffect of Different Doses of Ondansetron on Hemodynamic Status in Patients Undergoing Elective Caesarean Section Under Spinal Anaesthesia: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/index-e2c2f0a7774ed808Pharma Surgeen2026-07-06T00:00:00.000ZIndexhttps://www.pharmaradar360.com/article/979-effects-of-primary-tumor-and-its-ablation-on-the-growth-of-metastases-a-natu-7582c2f49f7609eePharma Surgeen2026-07-06T00:00:00.000Z979 Effects of primary tumor and its ablation on the growth of metastases: a natural lawhttps://www.pharmaradar360.com/article/747-the-laws-of-tumor-growth-c04d55320e9d4fa7Pharma Surgeen2026-07-06T00:00:00.000Z747 The laws of tumor growthhttps://www.pharmaradar360.com/article/monitorizacion-de-concentraciones-sericas-de-abiraterona-bf99eb88c512c768Pharma Surgeen2026-07-06T00:00:00.000ZMonitorización de concentraciones séricas de abirateronahttps://www.pharmaradar360.com/article/i-de-novo-arid1a-i-coffin-siris-syndrome-with-hypothyroidism-and-dyslipidemia-a-c1faeaa47e1f0c5bPharma Surgeen2026-07-06T00:00:00.000Z<i>De novo ARID1A</i> Coffin-Siris syndrome with hypothyroidism and dyslipidemia: A case report and literature reviewhttps://www.pharmaradar360.com/article/comparative-clinical-effectiveness-safety-and-cost-effectiveness-of-intravenous-990f8b734c66b833Pharma Surgeen2026-07-06T00:00:00.000ZComparative Clinical Effectiveness, Safety, and Cost-Effectiveness of Intravenous Tramadol versus Metamizole for Post-Procedural Pain Managementhttps://www.pharmaradar360.com/article/integration-of-genetic-evidence-to-identify-approved-drug-targets-0d9e59bb7356f437Pharma Surgeen2026-07-06T00:00:00.000ZIntegration of genetic evidence to identify approved drug targetshttps://www.pharmaradar360.com/article/virtual-reality-simulation-for-chemotherapy-drug-spill-management-training-in-ph-2f2cf8343adc9b44Pharma Surgeen2026-07-06T00:00:00.000ZVirtual reality simulation for chemotherapy drug spill management training in pharmacy education: A cohort-allocated crossover quasi-experimental study in Taiwanhttps://www.pharmaradar360.com/article/effects-of-tablet-based-augmented-reality-on-anxiety-fear-and-pain-during-venipu-5961a1fa33df4693Pharma Surgeen2026-07-06T00:00:00.000ZEffects of tablet-based augmented reality on anxiety, fear, and pain during venipuncture in children: a randomized controlled trialhttps://www.pharmaradar360.com/article/comprehensive-effects-of-occupational-therapy-using-ayres-sensory-integration-in-3134bec39f4bddd5Pharma Surgeen2026-07-06T00:00:00.000ZComprehensive Effects of Occupational Therapy Using Ayres Sensory Integration® in Children With ADHD: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/data-from-predicting-clinical-sensitivities-of-lt-i-gt-pdgfra-lt-i-gt-exon-18-mu-e86b0b68c01cc4afPharma Surgeen2026-07-06T00:00:00.000ZData from Predicting Clinical Sensitivities of &lt;i&gt;PDGFRA&lt;/i&gt; Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatmenthttps://www.pharmaradar360.com/article/figure-4-from-predicting-clinical-sensitivities-of-lt-i-gt-pdgfra-lt-i-gt-exon-1-87ebc7ca9583b025Pharma Surgeen2026-07-06T00:00:00.000ZFigure 4 from Predicting Clinical Sensitivities of &lt;i&gt;PDGFRA&lt;/i&gt; Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatmenthttps://www.pharmaradar360.com/article/supp-fig-2-from-predicting-clinical-sensitivities-of-lt-i-gt-pdgfra-lt-i-gt-exon-400494a6b026df3aPharma Surgeen2026-07-06T00:00:00.000ZSupp. Fig. 2 from Predicting Clinical Sensitivities of &lt;i&gt;PDGFRA&lt;/i&gt; Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatmenthttps://www.pharmaradar360.com/article/supp-fig-7-from-predicting-clinical-sensitivities-of-lt-i-gt-pdgfra-lt-i-gt-exon-729354e0b18125ffPharma Surgeen2026-07-06T00:00:00.000ZSupp. Fig. 7 from Predicting Clinical Sensitivities of &lt;i&gt;PDGFRA&lt;/i&gt; Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatmenthttps://www.pharmaradar360.com/article/supplementary-table-s2-from-predicting-clinical-sensitivities-of-lt-i-gt-pdgfra-d17abb5088d685ddPharma Surgeen2026-07-06T00:00:00.000ZSupplementary Table S2 from Predicting Clinical Sensitivities of &lt;i&gt;PDGFRA&lt;/i&gt; Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatmenthttps://www.pharmaradar360.com/article/supplementary-table-s5-from-predicting-clinical-sensitivities-of-lt-i-gt-pdgfra-bffa5c12b1d78905Pharma Surgeen2026-07-06T00:00:00.000ZSupplementary Table S5 from Predicting Clinical Sensitivities of &lt;i&gt;PDGFRA&lt;/i&gt; Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatmenthttps://www.pharmaradar360.com/article/the-69th-session-of-the-un-commission-on-narcotic-drugs-multilateral-drug-policy-8f999d9aab89dc87Pharma Surgeen2026-07-06T00:00:00.000ZThe 69th session of the UN Commission on Narcotic Drugs: multilateral drug policy navigating fragmentationhttps://www.pharmaradar360.com/article/surface-eeg-to-identify-cognitive-motor-dissociation-after-acute-brain-injury-4aa5c4cddaf2f337Pharma Surgeen2026-07-06T00:00:00.000ZSurface EEG to Identify Cognitive Motor Dissociation After Acute Brain Injuryhttps://www.pharmaradar360.com/article/recommendations-for-assessing-methodological-quality-in-systematic-reviews-of-po-61aa75ef3db5046cPharma Surgeen2026-07-06T00:00:00.000ZRecommendations for Assessing Methodological Quality in Systematic Reviews of Population Pharmacokinetic Models: A Systematic Reviewhttps://www.pharmaradar360.com/article/exercise-testing-in-contemporary-aortic-stenosis-management-translating-pathophy-8a05f8468bf3ee80Pharma Surgeen2026-07-06T00:00:00.000ZExercise testing in contemporary aortic stenosis management: translating pathophysiological insights into clinical decision-makinghttps://www.pharmaradar360.com/article/effect-of-early-skin-to-skin-contact-after-vaginal-birth-on-neonatal-stress-and-1784d183bfb990f1Pharma Surgeen2026-07-06T00:00:00.000ZEffect of early skin-to-skin contact after vaginal birth on neonatal stress and day-5 bilirubin levels: a randomized trialhttps://www.pharmaradar360.com/article/orelabrutinib-versus-chemoimmunotherapy-in-treatment-naive-chronic-lymphocytic-l-7a52382412224fc0Pharma Surgeen2026-07-06T00:00:00.000ZOrelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trialhttps://www.pharmaradar360.com/article/analysis-of-the-effectiveness-of-injection-based-minimally-invasive-treatment-fo-9d1db97586700775Pharma Surgeen2026-07-06T00:00:00.000ZAnalysis of the Effectiveness of Injection-Based Minimally Invasive Treatment for Piriformis Syndrome: Clinical Outcomes and Anatomical Correlateshttps://www.pharmaradar360.com/article/developmental-trajectories-in-young-autistic-children-receiving-parent-mediated-2bd0319e048f0758Pharma Surgeen2026-07-06T00:00:00.000ZDevelopmental Trajectories in Young Autistic Children Receiving Parent-Mediated Intervention Through In-Person and Telehealth Service Delivery Models: A Naturalistic, Nonrandomized Clinical Studyhttps://www.pharmaradar360.com/article/cutaneous-lesions-with-cryptococcus-like-changes-in-the-context-of-anca-vasculit-6ebccf988ddd45fdPharma Surgeen2026-07-06T00:00:00.000ZCutaneous lesions with Cryptococcus-like changes in the context of ANCA vasculitis: case reports and literature reviewhttps://www.pharmaradar360.com/article/perinatal-mental-health-issues-in-consultations-regarding-medication-use-during-20b158ac4aa3d606Pharma Surgeen2026-07-06T00:00:00.000ZPerinatal mental health issues in consultations regarding medication use during breastfeeding: Insights from the Japan Drug Information Institute in Pregnancy (JDIIP)https://www.pharmaradar360.com/article/the-use-of-pharmacodynamic-results-for-recommended-phase-ii-decision-making-in-o-937cc22e28152489Pharma Surgeen2026-07-06T00:00:00.000ZThe use of pharmacodynamic results for recommended phase II decision making in oncology clinical trialshttps://www.pharmaradar360.com/article/anticipated-online-harassment-and-potential-chilling-effects-on-mandatory-child-b20e51e2146a2838Pharma Surgeen2026-07-06T00:00:00.000ZAnticipated online harassment and potential chilling effects on mandatory child abuse reporting: A pilot survey of pediatricians in Japanhttps://www.pharmaradar360.com/article/optimizing-integrated-multienzyme-membrane-system-to-maximize-xylo-oligosacchari-6749eab588c10a55Pharma Surgeen2026-07-06T00:00:00.000ZOptimizing integrated multienzyme‐membrane system to maximize xylo‐oligosaccharide yield and eradicate inhibitors: addressing fouling and sugar purification in pineapple residue processinghttps://www.pharmaradar360.com/article/nct07684950-lisaftoclax-plus-pirtobrutinib-in-relapsed-or-refractory-mantle-cell-4038c7136e06fec1Pharma Surgeen2026-07-06T00:00:00.000ZNCT07684950: Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapyhttps://www.pharmaradar360.com/article/nct07684677-effect-of-participating-in-a-study-of-causes-of-pregnancy-loss-on-me-09028b0177f91d60Pharma Surgeen2026-07-06T00:00:00.000ZNCT07684677: Effect of Participating in a Study of Causes of Pregnancy Loss on Mental Health Outcomes: A Target Trial Emulation Using the COPL Cohort and Danish National Registrieshttps://www.pharmaradar360.com/article/nct07684560-phase-ib-randomized-double-blind-placebo-controlled-dose-escalation-ccaaffaaa4d1d45ePharma Surgeen2026-07-06T00:00:00.000ZNCT07684560: Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2).https://www.pharmaradar360.com/article/nct07684456-efficacy-and-safety-of-utidelone-capsule-and-utidelone-injection-in-0bb4ffdb99e569cePharma Surgeen2026-07-06T00:00:00.000ZNCT07684456: Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancerhttps://www.pharmaradar360.com/article/nct07684144-extension-trial-to-evaluate-the-long-term-efficacy-safety-and-tolera-f1adde852380bd2aPharma Surgeen2026-07-06T00:00:00.000ZNCT07684144: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)https://www.pharmaradar360.com/article/nct07683377-safety-and-efficacy-analysis-of-stent-assisted-coil-embolization-in-829d1c3bf7cebe5ePharma Surgeen2026-07-06T00:00:00.000ZNCT07683377: Safety and Efficacy Analysis of Stent-assisted Coil Embolization in the Treatment of Acute Ruptured Intracranial Aneurysms in the Perioperative Period.https://www.pharmaradar360.com/article/nct07683299-hemo-integra-integrated-intraoperative-hemodynamic-monitoring-during-50310beebf06d417Pharma Surgeen2026-07-06T00:00:00.000ZNCT07683299: HEMO-INTEGRA: Integrated Intraoperative Hemodynamic Monitoring During Cardiac Surgery With Cardiopulmonary Bypass - A Pilot Studyhttps://www.pharmaradar360.com/article/nct07682792-golidocitinib-in-patients-with-mycosis-fungoides-sezary-syndrome-and-d28090fab8007d18Pharma Surgeen2026-07-06T00:00:00.000ZNCT07682792: Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemiahttps://www.pharmaradar360.com/article/nct07667400-docetaxel-and-sx-682-in-recurrent-metastatic-head-and-neck-squamous-eb782075b524b62cPharma Surgeen2026-07-06T00:00:00.000ZNCT07667400: Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancerhttps://www.pharmaradar360.com/article/nct07661056-study-to-determine-if-bhv-1300-is-effective-and-safe-in-adults-with-4483952f1eaffc81Pharma Surgeen2026-07-06T00:00:00.000ZNCT07661056: Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Diseasehttps://www.pharmaradar360.com/article/nct07601113-pg2-breast-cancer-evaluation-in-adjuvant-medicine-survival-study-3a9b905db57067f3Pharma Surgeen2026-07-06T00:00:00.000ZNCT07601113: PG2 Breast Cancer Evaluation in Adjuvant Medicine-Survival Studyhttps://www.pharmaradar360.com/article/nct07447128-prospective-analysis-of-arteriovenous-access-ava-use-in-continuous-r-d90bd97a20fd8a1dPharma Surgeen2026-07-06T00:00:00.000ZNCT07447128: Prospective Analysis of Arteriovenous Access (AVA) Use in Continuous Renal Replacement Therapy: A Feasibility Projecthttps://www.pharmaradar360.com/article/nct07416188-novel-indenoisoquinolone-cmyc-topoisomerase-1-inhibitor-lmp744-in-re-dcf6d8e23b23af45Pharma Surgeen2026-07-06T00:00:00.000ZNCT07416188: Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastomahttps://www.pharmaradar360.com/article/nct07264114-aquatic-high-intensity-interval-training-for-parkinson-s-disease-049d7b03399b834dPharma Surgeen2026-07-06T00:00:00.000ZNCT07264114: Aquatic High-Intensity Interval Training for Parkinson's Diseasehttps://www.pharmaradar360.com/article/nct07174310-a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-iv-prasin-6ecdc429f43ff026Pharma Surgeen2026-07-06T00:00:00.000ZNCT07174310: A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Diseasehttps://www.pharmaradar360.com/article/nct07137442-distinguishing-tics-and-functional-tics-using-clinical-neurophysiolo-e0a0f7cc00953d72Pharma Surgeen2026-07-06T00:00:00.000ZNCT07137442: Distinguishing Tics and Functional Tics Using Clinical Neurophysiological Techniqueshttps://www.pharmaradar360.com/article/nct07082998-comparing-the-efficacy-of-heated-yoga-and-sauna-as-a-treatment-for-d-f81140ef3d03163cPharma Surgeen2026-07-06T00:00:00.000ZNCT07082998: Comparing the Efficacy of Heated Yoga and Sauna as a Treatment for Depressionhttps://www.pharmaradar360.com/article/nct07082049-ai-llm-communication-aid-in-prostate-cancer-care-ai-cap-bcb7df30b4037e7cPharma Surgeen2026-07-06T00:00:00.000ZNCT07082049: AI-LLM Communication Aid in Prostate Cancer Care (AI-CAP）https://www.pharmaradar360.com/article/nct07033494-a-clinical-study-of-mk-2214-in-people-with-early-alzheimer-s-disease-4d8d981d28c4f421Pharma Surgeen2026-07-06T00:00:00.000ZNCT07033494: A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)https://www.pharmaradar360.com/article/nct06991738-177lu-dota-eb-tate-in-adult-patients-with-metastatic-radioactive-iod-8bb88397e09523fdPharma Surgeen2026-07-06T00:00:00.000ZNCT06991738: 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancerhttps://www.pharmaradar360.com/article/nct06834152-online-adaptive-stereotactic-body-radiotherapy-for-localized-prostat-ad58c7fc3365f771Pharma Surgeen2026-07-06T00:00:00.000ZNCT06834152: Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancerhttps://www.pharmaradar360.com/article/nct06663319-a-study-of-jnj-89402638-for-metastatic-colorectal-and-gastric-cancer-a287e7e323b9bee8Pharma Surgeen2026-07-06T00:00:00.000ZNCT06663319: A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancershttps://www.pharmaradar360.com/article/nct06627413-safety-tolerability-and-pharmacokinetics-of-lumateperone-long-acting-3e7f7c343d03842bPharma Surgeen2026-07-06T00:00:00.000ZNCT06627413: Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorderhttps://www.pharmaradar360.com/article/nct06441266-m-part-in-head-and-neck-cancer-patients-treated-with-kerastat-cream-a482489463c5cf88Pharma Surgeen2026-07-06T00:00:00.000ZNCT06441266: M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitishttps://www.pharmaradar360.com/article/nct05957276-global-patient-registry-of-inherited-retinal-diseases-849088d42b4a5b65Pharma Surgeen2026-07-06T00:00:00.000ZNCT05957276: Global Patient Registry of Inherited Retinal Diseaseshttps://www.pharmaradar360.com/article/nct05870579-177lu-lu-neob-in-combination-with-ribociclib-and-fulvestrant-in-part-ca75c3464d1af339Pharma Surgeen2026-07-06T00:00:00.000ZNCT05870579: [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancerhttps://www.pharmaradar360.com/article/nct05657405-observational-study-of-advanced-data-analytics-in-genetic-conditions-50091b2d3c66f87aPharma Surgeen2026-07-06T00:00:00.000ZNCT05657405: Observational Study of Advanced Data Analytics in Genetic Conditionshttps://www.pharmaradar360.com/article/nct05138848-time-in-bed-restriction-in-older-adults-with-sleep-difficulties-with-98aa3c906081b4eePharma Surgeen2026-07-06T00:00:00.000ZNCT05138848: Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Diseasehttps://www.pharmaradar360.com/article/nct04722146-a-study-of-teclistamab-with-other-anticancer-therapies-in-participan-860c374b56686545Pharma Surgeen2026-07-06T00:00:00.000ZNCT04722146: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myelomahttps://www.pharmaradar360.com/article/nct04609566-brentuximab-vedotin-with-pembrolizumab-in-metastatic-solid-tumors-6b5b3695104fb662Pharma Surgeen2026-07-06T00:00:00.000ZNCT04609566: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumorshttps://www.pharmaradar360.com/article/nct04084678-study-of-ralinepag-on-exercise-capacity-by-cardiopulmonary-exercise-0ceeea6950dfe2d5Pharma Surgeen2026-07-06T00:00:00.000ZNCT04084678: Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjectshttps://www.pharmaradar360.com/article/nct03976843-prostate-specific-membrane-antigen-pmsa-based-pet-imaging-of-high-ri-c4d08be1aa574161Pharma Surgeen2026-07-06T00:00:00.000ZNCT03976843: Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancerhttps://www.pharmaradar360.com/article/nct03854552-a-study-in-healthy-men-tests-how-different-doses-of-bi-764198-are-ta-42df0f926d71a878Pharma Surgeen2026-07-06T00:00:00.000ZNCT03854552: A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated.https://www.pharmaradar360.com/article/nct03767244-a-study-of-apalutamide-in-participants-with-high-risk-localized-or-l-30e832050af738b6Pharma Surgeen2026-07-06T00:00:00.000ZNCT03767244: A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomyhttps://www.pharmaradar360.com/article/nct03684278-randomised-treatment-of-acute-pancreatitis-with-infliximab-double-bl-b84d8436090afd9bPharma Surgeen2026-07-06T00:00:00.000ZNCT03684278: Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)https://www.pharmaradar360.com/article/nct03533283-an-open-label-phase-lb-ii-study-of-glofitamab-and-atezolizumab-or-po-c5a2bc8b069e84b2Pharma Surgeen2026-07-06T00:00:00.000ZNCT03533283: An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphomahttps://www.pharmaradar360.com/article/nct03523442-a-study-of-androgen-receptor-ar-antagonist-apalutamide-in-chinese-pa-61d14108044c89c8Pharma Surgeen2026-07-06T00:00:00.000ZNCT03523442: A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancerhttps://www.pharmaradar360.com/article/nct03130244-procedure-for-duodenum-to-ileal-diversion-to-treat-type-2-diabetes-e288a3be4e1f37e8Pharma Surgeen2026-07-06T00:00:00.000ZNCT03130244: Procedure for Duodenum to Ileal Diversion to Treat Type 2 Diabeteshttps://www.pharmaradar360.com/article/nct02531516-an-efficacy-and-safety-study-of-jnj-56021927-apalutamide-in-high-ris-a1f5b9033cb6ad89Pharma Surgeen2026-07-06T00:00:00.000ZNCT02531516: An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAShttps://www.pharmaradar360.com/article/nct02123758-a-study-of-jnj-56021927-arn-509-and-abiraterone-acetate-in-participa-859727c05c2f2b2aPharma Surgeen2026-07-06T00:00:00.000ZNCT02123758: A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancerhttps://www.pharmaradar360.com/article/ix-biopharma-will-these-upcoming-milestones-re-rate-the-stock-f6d3fca056e5251fPharma Surgeen2026-07-05T23:47:50.000ZiX BIOPHARMA: Will These Upcoming Milestones Re-rate The Stock?https://www.pharmaradar360.com/article/abvx-stock-rockets-28-after-abivax-eases-drug-safety-concerns-with-fresh-clinica-0b3a00b0753a7019Pharma Surgeen2026-07-05T23:01:32.000ZABVX Stock Rockets 28% After Abivax Eases Drug Safety Concerns With Fresh Clinical Datahttps://www.pharmaradar360.com/article/united-parcel-service-inc-ups-eyes-medicines-and-pharmaceutical-opportunities-wi-2cd2af5be164263dPharma Surgeen2026-07-05T22:51:47.000ZUnited Parcel Service, Inc. (UPS) Eyes Medicines and Pharmaceutical Opportunities with $48M Investmenthttps://www.pharmaradar360.com/article/mbrx-stock-drops-25-as-moleculin-biotech-s-interim-cancer-trial-data-falls-short-d8f025f87aa6b36fPharma Surgeen2026-07-05T22:46:35.000ZMBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significancehttps://www.pharmaradar360.com/article/editorial-independent-drug-approvals-are-key-to-hong-kong-s-biotech-ambitions-ee78af063b415671Pharma Surgeen2026-07-05T22:45:07.000ZEditorial | Independent drug approvals are key to Hong Kong’s biotech ambitionshttps://www.pharmaradar360.com/article/does-crispr-therapeutics-crsp-russell-index-debut-quietly-reframe-its-biotech-gr-87c9577cd0edee75Pharma Surgeen2026-07-05T21:32:18.000ZDoes CRISPR Therapeutics’ (CRSP) Russell Index Debut Quietly Reframe Its Biotech Growth Narrative?https://www.pharmaradar360.com/article/biotech-etf-bbc-touches-a-new-52-week-high-34551354c9d74147Pharma Surgeen2026-07-05T19:29:29.000ZBiotech ETF (BBC) touches a new 52-week highhttps://www.pharmaradar360.com/article/the-hidden-reason-biotech-breakthroughs-keep-getting-delayed-a4cd1537cb3fbe8bPharma Surgeen2026-07-05T19:05:16.000ZThe Hidden Reason Biotech Breakthroughs Keep Getting Delayedhttps://www.pharmaradar360.com/article/texas-biomed-teams-up-with-uk-based-biotech-company-to-fight-screwworm-87325582fe823f51Pharma Surgeen2026-07-05T19:00:00.000ZTexas Biomed teams up with UK-based biotech company to fight screwwormhttps://www.pharmaradar360.com/article/cmps-stock-rises-23-pre-market-as-compass-achieves-primary-endpoint-in-phase-3-t-4191aa06fc271c3ePharma Surgeen2026-07-05T18:35:53.000ZCMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trialhttps://www.pharmaradar360.com/article/roche-collaborates-with-nurix-therapeutics-to-develop-btk-degrader-bexobrutideg-aecfe63314cca483Pharma Surgeen2026-07-05T18:04:35.000ZRoche collaborates with Nurix Therapeutics to develop BTK degrader bexobrutideg for cancer and immune diseaseshttps://www.pharmaradar360.com/article/meps-supportive-of-draft-biotech-report-but-divisions-over-incentives-remain-fff282b603d604e9Pharma Surgeen2026-07-05T16:21:39.000ZMEPs supportive of draft Biotech report, but divisions over incentives remainhttps://www.pharmaradar360.com/article/ihe-vs-pjp-which-pharmaceutical-etf-is-the-better-buy-for-investors-1688a53a9f740efcPharma Surgeen2026-07-05T16:16:00.000ZIHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors?https://www.pharmaradar360.com/article/viatris-inc-is-one-of-the-10-most-undervalued-nasdaq-stocks-to-buy-right-now-2d7153f45e5c5f71Pharma Surgeen2026-07-05T16:15:12.000ZViatris Inc. is One of the 10 Most Undervalued NASDAQ Stocks to Buy Right Nowhttps://www.pharmaradar360.com/article/biotech-stocks-are-surging-in-2026-this-one-stands-out-after-a-pullback-626f44075305061aPharma Surgeen2026-07-05T15:15:00.000ZBiotech Stocks Are Surging in 2026. This One Stands Out After a Pullback.https://www.pharmaradar360.com/article/price-to-sales-forward-of-collegium-pharmaceutical-inc-fwb-354-b43a7e826ec97bddPharma Surgeen2026-07-05T14:42:33.000ZPrice to sales forward of Collegium Pharmaceutical, Inc. – FWB:354https://www.pharmaradar360.com/article/price-to-book-forward-of-china-resources-jiangzhong-pharmaceutical-co-ltd-class-fd4c6270a154603fPharma Surgeen2026-07-05T14:23:21.000ZPrice to book forward of China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A – SSE:600750https://www.pharmaradar360.com/article/roche-reports-positive-phase-3-results-for-divarasib-in-previously-treated-kras-2eabe1a7abcc5efePharma Surgeen2026-07-05T14:15:04.000ZRoche Reports Positive Phase 3 Results for Divarasib in Previously Treated KRAS G12C NSCLChttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-ctt-pharmaceutical-holdings-inc-otc-ctth-81294a0696c4041dPharma Surgeen2026-07-05T14:13:33.000ZPrice to earnings forward of CTT Pharmaceutical Holdings, Inc. – OTC:CTTHhttps://www.pharmaradar360.com/article/maharashtra-fda-flags-three-beauty-creams-over-toxic-mercury-and-lead-levels-42396aaeb2809a02Pharma Surgeen2026-07-05T13:44:23.000ZMaharashtra FDA Flags Three Beauty Creams Over Toxic Mercury and Lead Levelshttps://www.pharmaradar360.com/article/maharashtra-fda-warns-against-three-beauty-creams-after-tests-detect-excessive-m-a206392656bc30acPharma Surgeen2026-07-05T13:39:09.000ZMaharashtra FDA warns against three beauty creams after tests detect excessive mercury, lead levelshttps://www.pharmaradar360.com/article/fidelity-health-care-vs-state-street-biotech-which-etf-fits-your-portfolio-best-911217dff7804f89Pharma Surgeen2026-07-05T13:35:01.000ZFidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?https://www.pharmaradar360.com/article/gni-group-acquires-ayumi-pharmaceutical-for-jpy-44-8-billion-about-276-million-25a51d94eb4252d8Pharma Surgeen2026-07-05T13:22:22.000ZGNI Group Acquires Ayumi Pharmaceutical For JPY 44.8 Billion (About $276 Million)https://www.pharmaradar360.com/article/viatris-vtrs-most-undervalued-nasdaq-stocks-to-buy-right-now-1ceefbec1c56a272Pharma Surgeen2026-07-05T13:18:09.000ZViatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now